Skip to main content

Table 2 Subgroup analyses for the two examples.

From: Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Qstatistics

Trial Group # trials Q, P-value, (%) Fixed Effect HR (CI) P-value Random Effects HR (CI) P-value
NSCLC data    
all 11 39.6 (1.97e-05) 74.8 0.84 (0.74-0.95) 5.42e-03 0.77 (0.59-0.99) 0.042
Cisplatin 8 22.2 (2.34e-03) 68.5 0.73 (0.63-0.85) 6.63e-05 0.70 (0.53-0.93) 0.014
Q int = 39.62 - (22.20 + 8.72) = 8.70 (p = 0.003)  
all* 11   0.84 (0.61-1.16) 0.21
Cervix data    
>14 days 11 12.76 (0.24) 22 1.25, (1.07,1.46) 0.005 1.27 (1.06,1.53) 0.0099
≤ 14 days 7 20.74 (0.002) 71 0.83, (0.69,1.00) 0.046 0.87 (0.60,1.25) 0.44
Q int = 44.48 - (12.76 + 20.74) = 10.98 (p = 9e-04)  
  1. Q int denotes the subgroup interaction test statistic. * denotes the Henmi-Copas analysis: which puts a 'random effects' confidence interval around the fixed effects estimate.